{
    "clinical_study": {
        "@rank": "10119", 
        "brief_summary": {
            "textblock": "PRIMARY: To evaluate the safety, tolerability, pharmacokinetics, and ethanol exposure of two\n      dose regimens and formulations of SC-52151.\n\n      SECONDARY: To evaluate the preliminary anti-HIV activity of these treatment regimens and the\n      relationship between day 14 plasma concentrations of SC-52151 and immunological and\n      virological markers and toxicity.\n\n      Since viral isolates with decreased susceptibility to the protease inhibitor SC-52151 occur\n      in vitro after multiple passages, and since prolonged post infectious effects occur in\n      vitro, comparison of two formulations, an elixir and a self-emulsifying drug delivery system\n      (SEDDS), is needed to determine the appropriate dose formulation for Phase II studies."
        }, 
        "brief_title": "A Phase I Randomized Dose/Formulation Comparison Study of SC-52151", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Since viral isolates with decreased susceptibility to the protease inhibitor SC-52151 occur\n      in vitro after multiple passages, and since prolonged post infectious effects occur in\n      vitro, comparison of two formulations, an elixir and a self-emulsifying drug delivery system\n      (SEDDS), is needed to determine the appropriate dose formulation for Phase II studies.\n\n      Patients are randomized to four treatment arms to receive SC-52151 elixir or SEDDS\n      formulation at 1 of 2 doses for 2 weeks, with follow-up for 14 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Required for patients with CD4 count <= 200 cells/mm3:\n\n          -  PCP prophylaxis using TMP/SMX or aerosolized pentamidine.\n\n        Allowed:\n\n          -  Topical antifungal agents.\n\n          -  Up to 1000 mg/day acyclovir as maintenance therapy for herpes simplex virus.\n\n          -  Antibiotics for bacterial infections.\n\n          -  Antipyretics, analgesics, nonsteroidal anti-inflammatory agents, antiemetics, and\n             methadone for symptomatic treatment.\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  CD4 count 150 - 500 cells/mm3.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Unable to tolerate the standard diet required for the study.\n\n          -  Unable to give informed consent.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Antiretrovirals and biologic response modifiers (including HIV vaccines).\n\n          -  Maintenance with ketoconazole, fluconazole, itraconazole, ganciclovir, foscarnet,\n             pyrimethamine, sulfadiazine, clindamycin, azithromycin, isoniazid, rifampin,\n             rifabutin, ethambutol, pyrazinamide, clofazimine, or clarithromycin.\n\n          -  Prophylaxis for Mycobacterial infection or fungal infections other than Candidiasis.\n\n          -  Allopurinol.\n\n          -  Omeprazole.\n\n          -  Astemizole.\n\n          -  Terfenadine.\n\n          -  Loratadine.\n\n          -  Psychotropics.\n\n          -  Phenylbutazone.\n\n          -  Barbiturates.\n\n          -  Benzodiazepines.\n\n          -  Monoamine oxidase inhibitors.\n\n          -  H-2 blockers.\n\n          -  Anticonvulsants.\n\n          -  Coumadin anticoagulants.\n\n          -  Oral contraceptives.\n\n          -  Antiarrhythmics.\n\n          -  Diltiazem.\n\n          -  Metronidazole.\n\n          -  Erythromycin.\n\n          -  Chloramphenicol.\n\n          -  Fluoroquinolones.\n\n          -  Disulfiram.\n\n          -  Erythropoietin.\n\n          -  G-CSF or GM-CSF.\n\n          -  Systemic corticosteroids.\n\n          -  Alcohol, including alcohol-containing medications.\n\n        Patients with the following prior conditions are excluded:\n\n          -  Unexplained temperature >= 38.5 C for any 7 days within the 30 days prior to study\n             entry.\n\n          -  Chronic diarrhea (>= three stools per day) for any 15 days within the 30 days prior\n             to study entry.\n\n          -  Malignancy other than basal or squamous cell carcinoma of the skin, cervical\n             intraepithelial neoplasia, and minimal Kaposi's sarcoma.\n\n        Prior Medication:\n\n        Excluded at any time:\n\n          -  Prior HIV protease inhibitor.\n\n        Excluded within 30 days prior to study entry:\n\n          -  Investigational drugs.\n\n          -  Recombinant erythropoietin.\n\n          -  G-CSF or GM-CSF.\n\n          -  Interferon or interleukin.\n\n          -  Any HIV-1 vaccine.\n\n        Excluded within 14 days prior to study entry:\n\n          -  Antiretrovirals.\n\n          -  Acute therapy for any opportunistic or other serious infection.\n\n          -  Therapy for malignancy.\n\n          -  Maintenance with ketoconazole, fluconazole, itraconazole, ganciclovir, foscarnet,\n             pyrimethamine, sulfadiazine, clindamycin, azithromycin, isoniazid, rifampin,\n             rifabutin, ethambutol, pyrazinamide, clofazimine, or clarithromycin.\n\n          -  Prophylaxis for Mycobacterial infection or fungal infections other than Candidiasis.\n\n        Excluded within 7 days prior to study entry:\n\n          -  Allopurinol.\n\n          -  Omeprazole.\n\n          -  Astemizole.\n\n          -  Terfenadine.\n\n          -  Loratadine.\n\n          -  Psychotropics.\n\n          -  Phenylbutazone.\n\n          -  Barbiturates.\n\n          -  Benzodiazepines.\n\n          -  Monoamine oxidase inhibitors.\n\n          -  H-2 blockers.\n\n          -  Anticonvulsants.\n\n          -  Coumadin anticoagulants.\n\n          -  Oral contraceptives.\n\n          -  Antiarrhythmics.\n\n          -  Diltiazem.\n\n          -  Metronidazole.\n\n          -  Erythromycin.\n\n          -  Chloramphenicol.\n\n          -  Fluoroquinolones.\n\n          -  Disulfiram.\n\n        Risk Behavior: Excluded:\n\n          -  History of substance or alcohol abuse.\n\n          -  Ingestion of more than 50 g alcohol daily within 6 months prior to study entry.\n\n          -  Recovered alcoholic."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": "48", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000806", 
            "org_study_id": "ACTG 282"
        }, 
        "intervention": {
            "intervention_name": "Telinavir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "HIV Protease Inhibitors"
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "HIV Protease Inhibitors"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "921036325"
                    }, 
                    "name": "Univ of California / San Diego Treatment Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "331361013"
                    }, 
                    "name": "Univ of Miami School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "432101228"
                    }, 
                    "name": "Ohio State Univ Hosp Clinic"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Randomized Dose/Formulation Comparison Study of SC-52151", 
        "overall_official": [
            {
                "last_name": "Fischl MA", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Richman DD", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Flexner C", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Para MF", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "citation": "Fischl MA, Richman DD, Flexner C, Meehan P, Para MF, Haubrich R, Cook J, Wood K, Karim A. Phase I study of two formulations and dose schedules of SC- 521151, A protease inhibitor. Natl Conf Hum Retroviruses Relat Infect (2nd). 1995 Jan 29-Feb 2:88"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000806"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 1995"
    }, 
    "geocoordinates": {
        "Johns Hopkins Hosp": "39.29 -76.612", 
        "Ohio State Univ Hosp Clinic": "39.961 -82.999", 
        "Univ of California / San Diego Treatment Ctr": "32.715 -117.157", 
        "Univ of Miami School of Medicine": "25.789 -80.226"
    }
}